Evidence and clinical considerations for the use of serotonin and norepinephrine reuptake inhibitors for the treatment of painful neuropathy

M. Sigler, A. Vandenberg, A. Thompson
{"title":"Evidence and clinical considerations for the use of serotonin and norepinephrine reuptake inhibitors for the treatment of painful neuropathy","authors":"M. Sigler, A. Vandenberg, A. Thompson","doi":"10.9740/MHC.2015.11.289","DOIUrl":null,"url":null,"abstract":"Abstract Introduction: Peripheral neuropathy is a painful condition that can lead to a reduction in quality of life. The pain, which stems from damaged, hyperexcitable neurons, does not respond to traditional analgesics. However, due to the underlying mechanism of pain, some antidepressants are effective in managing peripheral neuropathy. The purpose of this review is to evaluate the available literature on serotonin-norepinephrine reuptake inhibitors for the management of peripheral neuropathy and outline clinical considerations for choosing an agent. Methods: PubMed, Ovid/MEDLINE, and Scopus queries were conducted for relevant literature. Search types were limited to keyword searches and articles were limited to those published prior to March 31, 2015. Results: There were 19 randomized controlled trials included in this review. No articles were found investigating the use of desvenlafaxine, milnacipran, or levomilnacipran for treatment of neuropathy. Both duloxetine and venlafaxine improved pain severit...","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"18 1","pages":"289-295"},"PeriodicalIF":0.0000,"publicationDate":"2015-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mental Health Clinician","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9740/MHC.2015.11.289","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Abstract Introduction: Peripheral neuropathy is a painful condition that can lead to a reduction in quality of life. The pain, which stems from damaged, hyperexcitable neurons, does not respond to traditional analgesics. However, due to the underlying mechanism of pain, some antidepressants are effective in managing peripheral neuropathy. The purpose of this review is to evaluate the available literature on serotonin-norepinephrine reuptake inhibitors for the management of peripheral neuropathy and outline clinical considerations for choosing an agent. Methods: PubMed, Ovid/MEDLINE, and Scopus queries were conducted for relevant literature. Search types were limited to keyword searches and articles were limited to those published prior to March 31, 2015. Results: There were 19 randomized controlled trials included in this review. No articles were found investigating the use of desvenlafaxine, milnacipran, or levomilnacipran for treatment of neuropathy. Both duloxetine and venlafaxine improved pain severit...
使用血清素和去甲肾上腺素再摄取抑制剂治疗疼痛性神经病变的证据和临床考虑
摘要简介:周围神经病变是一种痛苦的状况,可导致生活质量下降。这种疼痛源于受损的、过度兴奋的神经元,对传统的镇痛药没有反应。然而,由于疼痛的潜在机制,一些抗抑郁药在治疗周围神经病变方面是有效的。本综述的目的是评估现有的关于血清素-去甲肾上腺素再摄取抑制剂治疗周围神经病变的文献,并概述选择药物的临床考虑。方法:检索PubMed、Ovid/MEDLINE、Scopus等相关文献。搜索类型仅限于关键词搜索,文章仅限于2015年3月31日之前发布的文章。结果:本综述纳入了19项随机对照试验。没有文章被发现调查使用地文拉法辛、米那西普兰或左旋米那西普兰治疗神经病变。度洛西汀和文拉法辛都能改善疼痛。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信